Skip to main content

Table 2 Comparative Analysis of Bevacizumab and Ranibizumab groups

From: Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Agent

Eyes

Number of injections(times)

Baseline BCVA(letters)

Baseline CRT(μm)

BCVA at the end of the first follow-up period(letters)

CRT at the end of the first follow-up period (μm)

Bevacizumab(IVB)

10

2.50 ± 0.85

53.30 ± 16.69

317.5 ± 86.41

75.10 ± 11.72

274.6 ± 26.95

Ranibizumab(IVR)

25

2.36 ± 0.757

57.36 ± 13.17

368.0 ± 101.2

72.60 ± 13.05

272.4 ± 61.56

P(IVB vs IVR)

 

0.438b

0.451a

0.141b

0.529b

0.270b

  1. a Statistical analysis performed by the sample t-test
  2. b Statistical analysis performed by the Mann–Whitney U test
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us